Cargando…

Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment

OBJECTIVE: Optical coherence tomography angiography (OCT-A) enables detailed visualisation of the vascular structure of choroidal neovascularisation (CNV). The aim of this study was to determine whether mathematically ascertained OCT-A vascular parameters of type 1 and type 2 CNV in exudative age-re...

Descripción completa

Detalles Bibliográficos
Autores principales: Faatz, Henrik, Farecki, Marie-Louise, Rothaus, Kai, Gutfleisch, Matthias, Pauleikhoff, Daniel, Lommatzsch, Albrecht
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936421/
https://www.ncbi.nlm.nih.gov/pubmed/31909194
http://dx.doi.org/10.1136/bmjophth-2019-000369
_version_ 1783483728099540992
author Faatz, Henrik
Farecki, Marie-Louise
Rothaus, Kai
Gutfleisch, Matthias
Pauleikhoff, Daniel
Lommatzsch, Albrecht
author_facet Faatz, Henrik
Farecki, Marie-Louise
Rothaus, Kai
Gutfleisch, Matthias
Pauleikhoff, Daniel
Lommatzsch, Albrecht
author_sort Faatz, Henrik
collection PubMed
description OBJECTIVE: Optical coherence tomography angiography (OCT-A) enables detailed visualisation of the vascular structure of choroidal neovascularisation (CNV). The aim of this study was to determine whether mathematically ascertained OCT-A vascular parameters of type 1 and type 2 CNV in exudative age-related macular degeneration (AMD) change during antivascular endothelial growth factor (anti-VEGF) treatment. The OCT-A vascular parameters were also compared with previously obtained activity parameters (fluid distribution on spectral domain OCT (SD-OCT)) to establish whether they could potentially be used as further ‘activity parameters’ for assessment of anti-VEGF treatment. METHODS AND ANALYSIS: We evaluated 27 eyes of 27 patients (mean follow-up 9.8 months) with type 1, type 2 or mixed CNV who had received anti-VEGF treatment (IVAN scheme). The parameters analysed were area (aCNV), total length of all vessels (tlCNV), overall number of vascular segments (nsCNV) and fractal dimension (FD) of the CNV. The changes in each of these parameters were correlated with the central foveal thickness (CFT). RESULTS: Regression and renewed perfusion of the CNV corresponded with the decrease or increase, respectively, of macular fluid distribution on SD-OCT. The increase and decrease of CFT during anti-VEGF treatment were highly significantly correlated with changes in FD (p<0.00001), aCNV (p<0.00001), tlCNV (p<0.00001) and nsCNV (p<0.00001). CONCLUSION: OCT-A enables detailed analysis of AMD with regard to FD, aCNV, tlCNV and nsCNV. As the changes in these parameters correlate closely with changes on SD-OCT, they can be used as new activity parameters, alongside fluid distribution, for assessment of treatment effect and as parameters of stabilisation or the need for repeated treatment.
format Online
Article
Text
id pubmed-6936421
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-69364212020-01-06 Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment Faatz, Henrik Farecki, Marie-Louise Rothaus, Kai Gutfleisch, Matthias Pauleikhoff, Daniel Lommatzsch, Albrecht BMJ Open Ophthalmol Original Research OBJECTIVE: Optical coherence tomography angiography (OCT-A) enables detailed visualisation of the vascular structure of choroidal neovascularisation (CNV). The aim of this study was to determine whether mathematically ascertained OCT-A vascular parameters of type 1 and type 2 CNV in exudative age-related macular degeneration (AMD) change during antivascular endothelial growth factor (anti-VEGF) treatment. The OCT-A vascular parameters were also compared with previously obtained activity parameters (fluid distribution on spectral domain OCT (SD-OCT)) to establish whether they could potentially be used as further ‘activity parameters’ for assessment of anti-VEGF treatment. METHODS AND ANALYSIS: We evaluated 27 eyes of 27 patients (mean follow-up 9.8 months) with type 1, type 2 or mixed CNV who had received anti-VEGF treatment (IVAN scheme). The parameters analysed were area (aCNV), total length of all vessels (tlCNV), overall number of vascular segments (nsCNV) and fractal dimension (FD) of the CNV. The changes in each of these parameters were correlated with the central foveal thickness (CFT). RESULTS: Regression and renewed perfusion of the CNV corresponded with the decrease or increase, respectively, of macular fluid distribution on SD-OCT. The increase and decrease of CFT during anti-VEGF treatment were highly significantly correlated with changes in FD (p<0.00001), aCNV (p<0.00001), tlCNV (p<0.00001) and nsCNV (p<0.00001). CONCLUSION: OCT-A enables detailed analysis of AMD with regard to FD, aCNV, tlCNV and nsCNV. As the changes in these parameters correlate closely with changes on SD-OCT, they can be used as new activity parameters, alongside fluid distribution, for assessment of treatment effect and as parameters of stabilisation or the need for repeated treatment. BMJ Publishing Group 2019-12-10 /pmc/articles/PMC6936421/ /pubmed/31909194 http://dx.doi.org/10.1136/bmjophth-2019-000369 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Faatz, Henrik
Farecki, Marie-Louise
Rothaus, Kai
Gutfleisch, Matthias
Pauleikhoff, Daniel
Lommatzsch, Albrecht
Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment
title Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment
title_full Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment
title_fullStr Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment
title_full_unstemmed Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment
title_short Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment
title_sort changes in the oct angiographic appearance of type 1 and type 2 cnv in exudative amd during anti-vegf treatment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936421/
https://www.ncbi.nlm.nih.gov/pubmed/31909194
http://dx.doi.org/10.1136/bmjophth-2019-000369
work_keys_str_mv AT faatzhenrik changesintheoctangiographicappearanceoftype1andtype2cnvinexudativeamdduringantivegftreatment
AT fareckimarielouise changesintheoctangiographicappearanceoftype1andtype2cnvinexudativeamdduringantivegftreatment
AT rothauskai changesintheoctangiographicappearanceoftype1andtype2cnvinexudativeamdduringantivegftreatment
AT gutfleischmatthias changesintheoctangiographicappearanceoftype1andtype2cnvinexudativeamdduringantivegftreatment
AT pauleikhoffdaniel changesintheoctangiographicappearanceoftype1andtype2cnvinexudativeamdduringantivegftreatment
AT lommatzschalbrecht changesintheoctangiographicappearanceoftype1andtype2cnvinexudativeamdduringantivegftreatment